✦ LIBER ✦

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Scribed by Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee; The Korean Multiple Myeloma Working Party (KMMWP)

Publisher: Springer
Year: 2009
Tongue: English
Weight: 175 KB
Volume: 89
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-009-0856-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined thalidomide and cyclophosphamid

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study

✍ Sjoerd Hovenga; Simon M. G. J. Daenen; Joost T. M. de Wolf; Gustaaf W. van Imhof 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

Phase II study of CLAD (cyclophosphamide

Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)

✍ G. Hütter; H. Szélenyi; A. Schmittel; J. M. Siehl; E. Thiel; U. Keilholz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract The purpose of this study was to assess the efficacy and safety of pegylated liposomal doxorubicin in combination with cyclophosphamide and dexamethasone (CLAD). In this prospective open‐label phase II study, 60 patients with advanced multiple myeloma (MM) received three weekly cycles o

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views